BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38200396)

  • 1. Combination of [
    Kim J; Lee S; Kim D; Kim HJ; Oh KT; Kim SJ; Choi YD; Giesel FL; Kopka K; Hoepping A; Lee M; Yun M
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1763-1772. PubMed ID: 38200396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.
    Donswijk ML; Ettema RH; Meijer D; Wondergem M; Cheung Z; Bekers EM; van Leeuwen PJ; van den Bergh RCN; van der Poel HG; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1741-1752. PubMed ID: 38273003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Performance of RECIP 1.0 Based on [
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
    J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of
    Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
    Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    Shanmugasundaram R; Saad J; Heyworth A; Wong V; Pelecanos A; Arianayagam M; Canagasingham B; Ferguson R; Goolam AS; Khadra M; Kam J; Ko R; McCombie S; Varol C; Winter M; Mansberg R; Nguyen D; Bui C; Loh H; Le K; Roberts MJ
    BJU Int; 2024 Feb; 133 Suppl 3():25-32. PubMed ID: 37943964
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flare on [
    Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice.
    Alongi P; Messina M; Pepe A; Arnone A; Vultaggio V; Longo C; Fiasconaro E; Mirabile A; Ricapito R; Blasi L; Arnone G; Messina C
    Nucl Med Commun; 2024 Jul; 45(7):622-628. PubMed ID: 38835182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined whole-body dynamic and static PET/CT with low-dose [
    Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of
    Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.
    McGeorge S; Kwok M; Jiang A; Emmett L; Pattison DA; Thomas PA; Yaxley JW; Roberts MJ
    Adv Urol; 2021; 2021():1544208. PubMed ID: 34456998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
    Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection Efficacy of
    Giesel FL; Knorr K; Spohn F; Will L; Maurer T; Flechsig P; Neels O; Schiller K; Amaral H; Weber WA; Haberkorn U; Schwaiger M; Kratochwil C; Choyke P; Kramer V; Kopka K; Eiber M
    J Nucl Med; 2019 Mar; 60(3):362-368. PubMed ID: 30042163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
    Morawitz J; Kirchner J; Lakes J; Bruckmann NM; Mamlins E; Hiester A; Aissa J; Loberg C; Schimmöller L; Arsov C; Antke C; Albers P; Antoch G; Sawicki LM
    Eur J Radiol; 2021 Mar; 136():109556. PubMed ID: 33485127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.